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Abstract
Variants in the growth factor receptor-bound protein 10 (GRB10) gene were in a GWAS meta-analysis associated with
reduced glucose-stimulated insulin secretion and increased risk of type 2 diabetes (T2D) if inherited from the father, but
inexplicably reduced fasting glucose when inherited from the mother. GRB10 is a negative regulator of insulin signaling and
imprinted in a parent-of-origin fashion in different tissues. GRB10 knock-down in human pancreatic islets showed reduced
insulin and glucagon secretion, which together with changes in insulin sensitivity may explain the paradoxical reduction of
glucose despite a decrease in insulin secretion. Together, these findings suggest that tissue-specific methylation and
possibly imprinting of GRB10 can influence glucose metabolism and contribute to T2D pathogenesis. The data also
emphasize the need in genetic studies to consider whether risk alleles are inherited from the mother or the father.
Citation: Prokopenko I, Poon W, Ma¨gi R, Prasad B R, Salehi SA, et al. (2014) A Central Role for GRB10 in Regulation of Islet Function in Man. PLoS Genet 10(4):
e1004235. doi:10.1371/journal.pgen.1004235
Editor: Scott M. Williams, Dartmouth College, United States of America
Received June 8, 2013; Accepted January 20, 2014; Published April 3, 2014
This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for
any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.
PLOS Genetics | www.plosgenetics.org 1 April 2014 | Volume 10 | Issue 4 | e1004235
Funding: Studies at LUDC in Malmo¨ (DGI, BPS, PPP, MPP and human islets) were supported by grants from the Swedish Research Council (SFO EXODIAB: Dnr 2009-
1039), Linnaeus grant (LUDC Dnr 349-2008-6589), project grants to VLy, LG, NW, and CLi, and financial support from the Swedish Research Council (Dnr 521-2010-3490,
Dnr 521-2010-3490, Dnr 521-2010-3490, Dnr 521-2007-4037, Dnr 521-2008-2974, ANDIS Dnr 825-2010-5983), the Knut & Alice Wallenberg foundation (KAW
2009.0243), the Torsten och Ragnar So¨derbergs Stiftelser (MT33/09), the Inga Britt och Arne Lundberg’s Research Foundation (grant nr. 359), the Heart and Lung
Foundation, the Novo Nordisk foundation, Diabetes Research & Wellness, Sydva¨stra Ska˚nes Diabetesfo¨rening. The PPP-Botnia study was supported by grants from the
Sigrid Juselius Foundation, the Finnish Diabetes Research Society, the Signe and Ane Gyllenberg Foundation, the Swedish Cultural Foundation in Finland, the Ollqvist
Foundation, the Foundation for Life and Health in Finland, Jakobstad Hospital, the Medical Society of Finland, the Na¨rpes Research Foundation and the Vasa and
Na¨rpes Health centers. The MPP study was supported by a grant from the Swedish Heart and Lung Foundation, the E. Lundstro¨m Foundation and from the Region
Ska˚ne County Council funds. The RISC Study was supported by European Union grant QLG1-CT-2001-01252 and AstraZeneca. The Amish Family Diabetes Study was
supported by NIH research grants R01 DK54261, R01 DK68495, U01 HL84756, the University of Maryland General Clinical Research Center (M01 RR16500), Hopkins
Bayview General Clinical Research Center (M01 RR02719), the Mid-Atlantic Nutrition Obesity Research Center (P30 DK072488), the Baltimore Diabetes Research and
Training Center grant (P60 DK79637), the Baltimore Veterans Administration Geriatric Research and Education Clinical Center, and by USDA NIFA NRI Competitive
Grant 2007-35205-17883. The DR’s EXTRA Study was supported by grants to RR by the Ministry of Education and Culture of Finland (627;2004-2011), Academy of
Finland (102318; 123885), Kuopio University Hospital, Finnish Diabetes Association, Finnish Heart Association, Pa¨ivikki and Sakari Sohlberg Foundation and by grants
from European Commission FP6 Integrated Project (EXGENESIS), LSHM-CT-2004-005272, City of Kuopio and Social Insurance Institution of Finland (4/26/2010). The
METSIM Study was supported by grants from the Academy of Finland (141069, 141226), Diabetes Research Foundation, and Sigrid Juselius Foundation. The ULSAM
project was supported by grants from the Swedish Research Council, the Swedish Heart-Lung Foundation, the Swedish Foundation for Strategic Research, the Royal
Swedish Academy of Sciences, Swedish Diabetes Foundation, Swedish Society of Medicine, and Novo Nordisk Foundation. Part of the genotyping in ULSAM for this
project was supported through the ENGAGE (European Network for Genetic and Genomic Epidemiology) Consortium, which is funded through the European
Community’s Seventh Framework Programme (HEALTH-F4-2007- 201413). The SNP & SEQ Technology Platform in Uppsala was supported by Science for Life
Laboratory and the Swedish Research Council for Infrastructures (RFI). The Sorbs work was supported by grants from the German Research Council (DFG - SFB 1052
‘‘Obesity mechanisms’’; A01, B03, C01), from the German Diabetes Association and from the DHFD (Diabetes Hilfs- und Forschungsfonds Deutschland). IFB Adiposity
Diseases is supported by the Federal Ministry of Education and Research (BMBF), Germany, FKZ: 01EO1001. PK is funded by Boehringer Ingelheim Foundation. RM
acknowledges financial support from the European Commission under a Marie Curie Intra-European Fellowship, EFSD New Horizons grant, and Development Fund of
the University of Tartu, in the frame of the Centre of Transitional Genomics (grant SP1GVARENG) and by Estonian Government (grant #SF0180142s08). The research of
IP and VLa was funded in part through the European Community’s Seventh Framework Programme (FP7/2007-2013), ENGAGE project, grant agreement HEALTH-F4-
2007-201413. Helsinki Birth Cohort Study (HBCS) has been supported by grants from the Academy of Finland (Grant No. 120386 and 125876 to JGE), the Finnish
Diabetes Research Society, Folkha¨lsan Research Foundation, Novo Nordisk Foundation, Finska La¨karesa¨llskapet, Liv och Ha¨lsa, the Wellcome Trust (Grant No. 89061/Z/
09/Z and 089062/Z/09/Z), Samfundet Folkha¨lsan, Finska La¨karesa¨llskapet, the Signe and Ane Gyllenberg foundation, the Univeristy of Helsinki, Ministry of Education,
Ahokas Foundation, Emil Aaltonen Foundation, European Science Foundation (EUROSTRESS), Juho Vainio Foundation, and Wellcome Trust (grant WT089062). MIM is a
Wellcome Trust Senior Investigator, and an NIHR Senior Investigator, and has also received funding from EU Framework 7: ENGAGE Consortium HEALTH-F4-2007-
201413, Wellcome Trust: 083270, 090367, 090532, 098381, Medical Research Council: G0601261 and Diabetes UK: RD08/0003704. The funders had no role in study
design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: I have read the journal’s policy and we have the following conflicts: VLy declares that Steno Diabetes Center is owned by Novonordisk, PK is
funded by Boehringer Ingelheim Foundation, TF received payment for lectures from MSD (Merck), AM is a consultant for Eli Lilly and Poxel and has received grants
from Eli Lilly and Boehringer Ingelheim, BI has received payment for lectures from Boehringer Ingelheim, MSD, Novo Nordisk Farma and AstraZeneca, LG has been a
consultant for and served on advisory boards for Sanofi-Aventis, GSK, Novartis, Merck, Tethys Bioscience and Xoma, and received lecture fees from Lilly and Novartis.
We confirm that these affiliations do not alter the adherence to all the PLOS Genetics policies on sharing data and materials.
* E-mail: Leif.Groop@med.lu.se (LG); vlly@steno.dk, Valeriya.Lyssenko@med.lu.se (VL)
. These authors contributed equally to this work.
Introduction
Type 2 diabetes (T2D) is a multifactorial polygenic disease, in
which genes interact with environmental and genetic factors to
unmask the disease. To date, genome-wide association studies
(GWAS) have identified more than 65 variants increasing risk of
T2D [1–8]. Many of the identified variants seem to influence the
capacity of b-cells to cope with increased insulin demands imposed
by insulin resistance [9,10]. Despite this, no GWAS to date has
explored the extent to which common genetic variants influence
dynamic measures of insulin secretion and action. Therefore, we
have here performed the first large-scale meta-analysis for glucose-
stimulated insulin secretion (GSIS) during an oral glucose
tolerance test (OGTT). Association analyses included a GWAS-
based discovery stage and a replication stage using a custom-
designed iSelect CardioMetabochip array containing 93,896 SNPs
overlapping with the discovery GWAS imputed from the
HapMap2 reference panel in up to 10,831 non-diabetic individ-
uals. We identified variants in the growth factor receptor-bound
protein 10 (GRB10) gene (NCBI Gene ID: 2887) to be associated
with impaired b-cell function at a genome-wide significant level
(p,561028). Since GRB10 has been shown to have parent-of-
origin specific effects on expression in various tissues [11,12], we
investigated the transmission patterns of the risk alleles and their
effects on insulin and glucose levels during an OGTT, risk for
T2D, expression of GRB10 and methylation status in human
pancreatic islets, as well as evaluated the effects on islet function
through disruption of GRB10 in human pancreatic islets.
Results
Meta-Analysis of GWAS and CardioMetabochip Studies
for Insulin Secretion and Action during an OGTT
We conducted a meta-analysis for dynamic measures of insulin
response to glucose during an OGTT using GWAS, CardioMeta-
bochip and de novo genotyping. The combined analysis in up to
26,037 non-diabetic individuals provided genome-wide significant
association (p,561028) with insulin secretion measured as correct-
ed insulin response (CIR) to glucose at 30 min during an OGTT for
the locus within the GRB10 gene (lead SNP rs933360 located in
intron 2) (Figure 1A, B), and at 7 previously reported T2D and
glycemic trait variants, including MTNR1B, HHEX/IDE/KIF11,
CDKAL1, GIPR/QPCTL, C2CD4A (NLF1), GCK and ANK1 (Table 1,
Table S2A, Figure S1, S2). These associations remained virtually
unchanged when CIR was adjusted for insulin sensitivity (disposi-
tion index) (Table S2A). In addition, nominal (p,0.05) association
with reduced insulin response to glucose (CIR) during the OGTT
was seen for the risk alleles in 24 out of 65 reported T2D loci [4], as
well as for 20 glucose and 7 insulin loci out of 53 reported being
associated with these traits [6]. Notably, the risk alleles in 5 of them
(ANKRD55, GRB14, PPP1R3B, IRS1 and ARAP1 (fasting glucose
variant)) were associated with higher insulin response to glucose
(p,0.05) (Table S2B).
In line with a previous report [6], we confirmed the association
of the index GRB10 SNP rs933360 with fasting glucose levels
(N = 24,608, b=20.016, p = 0.007) (Figure S3). However, we did
not observe a significant effect of SNP rs2237457, previously
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associated with glucose concentrations and risk for T2D in an
Amish population [13].
Since GRB10 is differentially expressed when transmitted from
mothers and fathers, we explored whether the GRB10 variant would
have sex-specific effects on insulin and glucose levels. The sex-
stratified analysis showed a greater insulin-reducing effect of the
GRB10 variant in women (CIR: N = 6,202; b=20.11060.019;
p = 1.5261028) than in men (CIR: N = 15,192; b=20.03860.012;
p = 0.0012; sex heterogeneity p= 0.0016) (Figure 1C, D).
Complex Pattern of Genetic Inheritance for Variants in
the GRB10 Gene: Evidence for Parent-of-Origin Effects
Given the complex parent-of-origin imprinting pattern de-
scribed for GRB10, we next turned to families to explore in detail
the inheritance patterns of identified variants and their potential
effect on risk of T2D and insulin/glucose levels. Using a cohort of
2,322 parents-offspring trios with 4,182 individuals from Finland
and Sweden, we first performed a transmission disequilibrium test,
taking into account the parental phenotype being either T2D
or not, to increase power (parenTDT) [14]. We also used gene-
dropping permutation to control for stratification and the depen-
dence of related individuals [14], or restricting the analysis to
independent trios, including only the youngest affected offspring
(N = 1,055; 182 with T2D) and oldest unaffected offspring
(N = 1,019; 873 unaffected). We observed an increased transmis-
sion of the A-allele of rs933360 from parents to diabetic offspring
(p = 0.0063) (Table S3A-I), particularly from diabetic fathers
(p = 0.049) (Table S3A-V), and the G-allele was preferentially
transmitted from non-diabetic parents to non-diabetic offspring
(p = 0.026) (Table S3A-II). In accordance with these findings, when
simply counting transmission of the A- and G-alleles, we observed
an increased transmission of the major A-allele of rs933360 from
a diabetic parent to a diabetic offspring (Chi-square p = 0.017)
(Table S3A-V). This effect was even stronger when we relaxed the
definition of hyperglycemia to include IFG and IGT in addition to
T2D (p = 0.006) (Table S3A-VI).
We observed a similar pattern of an increased transmission of
the T-allele of rs6943153 (LD with rs933360; D9= 0.99, r2 = 0.82)
to a hyperglycemic offspring (IFG/IGT/T2D) (p = 0.0045) (Table
S3A-III). This latter association was confirmed using the Family
Based Association Test (FBAT) [15] (p = 0.035), which can
accommodate any type of genetic model and family construction.
Consistent with previous findings [6], we confirmed the association
of the SNP rs6943153 with fasting glucose levels (1,083 nuclear
families, p = 0.02) (Table S3A-VII).
To explore whether GRB10 rs933360 would show a stronger
effect on insulin secretion when inherited from either parent, we
examined its effect on GSIS in 3,117 non-diabetic individuals from
parents-offspring trios from Finland and Sweden [16] and USA
[13]. In these families, the maternally transmitted A-allele of
rs933360 was associated with reduced GSIS (CIR b=20.127,
p = 0.014; Ins30adjBMI b=20.125, p = 0.005; Ins30 b=20.112,
p= 0.014; AUCIns b=20.095, p = 0.016; AUCIns/AUCGluc
b= 0.107, p = 0.005) (Figure 2A, B, Table S3B). No significant
effect was observed for the paternally transmitted A-allele on
GSIS. Surprisingly, the maternally transmitted A-allele was
associated with reduced rather than elevated fasting glucose levels
(b=20.139, p = 0.0009). In contrast, the paternally transmitted A-
allele was associated with elevated glucose levels (b= 0.102,
p = 0.002) (Figure 2C, D, Table S3B). Thereby, the A-allele of
rs933360 exerted virtually opposite effects on glucose metabolism
if transmitted from the father than the mother. It is very likely that
the association with risk or protection from T2D would be missed
or diluted in any traditional association study, which does not take
the transmission pattern into account.
In support of this, we did not observe any association between
the SNP rs933360 and T2D in 16,715 non-diabetic individuals, of
whom 2,637 developed T2D during a mean 25-year follow-up
period (Table S4) [17]. Also, in the recent DIAGRAM+ meta-
analysis, none of the evaluated GRB10 SNPs were associated with
T2D [4].
A potential explanation for the paradoxical reduction in glucose
levels despite reduced insulin secretion could be that the variant
also enhances insulin sensitivity or reduces glucagon levels. In fact,
the maternally transmitted A-allele was associated with enhanced,
whereas the paternally transmitted A-allele was associated with
decreased insulin sensitivity as measured by ISI during the OGTT
(p,0.05 for difference between parental alleles). Although we
could not observe any significant effect of rs933360 on fasting or
2 hr glucagon levels in a Finnish cohort with glucagon data
available (Table S5B), we identified several GRB10 SNPs from the
same haplotype block which were in weak LD with rs933360 and
nominally (p,0.05) associated with fasting and 2 hr glucagon
levels in the DGI GWAS (Table S6). Unfortunately, there was no
glucagon data available for the trios.
Effects of GRB10 rs933360 on Gene Expression
GRB10 protein was detected in human a-, b- and d-cells by
immunofluorescence (Figure 3A). We observed strong expression
of GRB10 mRNA in total human islets, with no significant
difference between islets from normoglycemic and hyperglycemic
individuals (Figure S4A), or between carriers of different GRB10
genotypes (Figure S4B).
While we did not observe any correlation between the amount
of GRB10 and INS (insulin) mRNA, nor between GRB10 mRNA
and in vitro GSIS, there was an inverse correlation between GRB10
and GCG (glucagon) mRNA in human pancreatic islets (all donors:
rho =20.267, p = 0.017; normoglycemic: rho =20.228, p= 0.10;
hyperglycemic: rho =20.651, p = 0.00003), suggesting that higher
GRB10 expression is associated with lower glucagon (Figure S4C).
Author Summary
In this paper, we report the first large genome-wide
association study in man for glucose-stimulated insulin
secretion (GSIS) indices during an oral glucose tolerance
test. We identify seven genetic loci and provide effects on
GSIS for all previously reported glycemic traits and obesity
genetic loci in a large-scale sample. We observe paradox-
ical effects of genetic variants in the growth factor
receptor-bound protein 10 (GRB10) gene yielding both
reduced GSIS and reduced fasting plasma glucose
concentrations, specifically showing a parent-of-origin
effect of GRB10 on lower fasting plasma glucose and
enhanced insulin sensitivity for maternal and elevated
glucose and decreased insulin sensitivity for paternal
transmissions of the risk allele. We also observe tissue-
specific differences in DNA methylation and allelic imbal-
ance in expression of GRB10 in human pancreatic islets. We
further disrupt GRB10 by shRNA in human islets, showing
reduction of both insulin and glucagon expression and
secretion. In conclusion, we provide evidence for complex
regulation of GRB10 in human islets. Our data suggest that
tissue-specific methylation and imprinting of GRB10 can
influence glucose metabolism and contribute to T2D
pathogenesis. The data also emphasize the need in genetic
studies to consider whether risk alleles are inherited from
the mother or the father.
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Figure 1. GWAS plots identifying GRB10 rs933360. Genome-wide quantile-quantile (Q-Q) (A) and Manhattan (B) plots for CIR in the meta-
analysis. Regional plots of identified GRB10 genome-wide significant association for CIR in men (C) and women (D). Directly genotyped and/or
imputed SNPs of GRB10 are plotted with their meta-analysis p-values (as 2log10 values) as a function of genomic position (NCBI Build 36). In each
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Although there was no effect of rs933360 on total GRB10
mRNA expression in human islets, we cannot exclude that the
variant could influence splicing or methylation, especially as 3
different transcriptional start sites (UN1, UN1a and UN2) and
tissue-specific expression have been described for the GRB10 gene
(Figure 3b, S5) [12].
We tested for allelic imbalance, i.e. deviation from the expected
equal expression of both alleles. For this purpose, we used the SNP
rs1800504 (ARG) located in exon 3 as a reporter SNP, as it is the
nearest coding variant located 16 kb from the index SNP rs933360
(D9= 1, r2 = 0.5). This reporter SNP indicated a clear allelic
imbalance with A- to G-allele ratios ranging from 35% to 75% in
pancreatic islets (Table S7). We therefore examined whether the
observed allelic imbalance could be related to specific transcripts
arising from different promoters. Transcripts containing exon
UN2 were monoallelically expressed from either the A- or G-
allele, indicating imprinting of the promoter giving rise to the UN2
transcripts (pUN2) from one parent. Until now, paternally
expressed (i.e. maternally imprinted) UN2 transcripts have only
been observed in the brain [12]. This differential imprinting was
recurring in all tissues analyzed (Figure S6). Our findings extend
this expression pattern to human islets. In contrast, transcripts
containing exon UN1 showed great variation (from 50% to 80%),
but were mainly expressed from the other allele than those
containing exon UN2 (Figure 3B, C), in line with the maternally
expressed/paternally imprinted transcripts observed in placental
trophoblasts [12]. It can be hypothesized that these SNPs might
regulate usage of alternative promoters and thereby influence
the expression of GRB10. The opposite effects of maternally
and paternally inherited rs933360 allele could then be attributed
to different effects of rs933360 on the promoters pUN2 and pUN1,
e.g. especially if promoter preferences differ strongly between a-
and b-cells.
Although allelic imbalance is an attractive model to explain
differences in expression of different GRB10 transcripts, as well as
the observed differences in effects of the A-allele on risk of diabetes
in the offspring when transmitted from father or from mother, the
above data can only point at this possibility, as we did not have
enough human islets for this kind of analysis. We therefore also
tested for allelic imbalance using an alternative method, i.e. by
comparing data from exome and RNA sequencing. We found that
another coding variant, SNP rs11555134, in the GRB10 gene was
associated with allelic imbalance in 8 human pancreatic islet
samples (p,0.05, Fisher’s exact test).
Since GRB10 is imprinted and methylated in humans and
rodents in a tissue-specific fashion [12,18,19], we studied whether
GRB10 would be methylated in human islets or in DNA from
human peripheral blood lymphocytes (PBL) and whether the
degree of the DNA methylation would correlate with gene
expression in human islets. We found tissue-specific differences
in DNA methylation of GRB10 in human islets compared to PBL
and the degree of methylation in the region analyzed with the
Sequenom MassARRAY EpiTYPER ranged from 56.9% to
99.8% (Figure 3D). Although we did not observe any significant
effect of rs933360 on the degree of DNA methylation in human
islets (Figure S7A), there was a nominal association between
rs933360 and DNA methylation in PBL in the region analyzed
using EpiTYPER (p= 0.07) (Figure S7B). Moreover, we observed
an inverse correlation between DNA methylation at a CpG site
located 31.7 kb downstream of rs933360 and GRB10 mRNA
expression (N = 81, rho =20.335, p= 0.002) (Figure 3E) in human
islets, particularly in islets from diabetic donors (N = 24,
rho =20.656, p= 0.001), and at a CpG site 8,196 bp downstream
from rs933360 (N = 66, rho =20.23, p= 0.047) (Figure S7C),
suggesting that decreased methylation in this region is associated
with increased GRB10 mRNA.
panel, the strongest associated SNP is represented by a purple diamond (with meta-analysis p-value). Estimated recombination rates (taken from
HapMap) are plotted to reflect the local linkage disequilibrium structure around the associated SNPs and their correlated proxies (according to a blue
to red scale from r2 = 0 to 1, based on pairwise r2 values from HapMap CEU). Gene annotations were taken from the University of California, Santa
Cruz, genome browser, as implemented in LocusZoom [41].
doi:10.1371/journal.pgen.1004235.g001
Table 1. SNPs associated with primary insulin secretion traits at genome-wide significance levels.






Effect SE p Effect SE p
Identified in the present study
rs933360 GRB10 26,037 A/G 0.62 20.051 0.0086 3.1461029 20.043 0.0087 8.1361027
Previously reported loci
rs10830963 MTNR1B 10,651 G/C 0.69 20.17 0.016 6.71610228 20.057 0.017 0.00062
rs7923866 HHEX/IDE 10,418 C/T 0.62 20.12 0.015 4.16610216 20.093 0.015 1.3761029
rs7756992 CDKAL1 10,829 G/A 0.3 20.11 0.015 3.07610213 20.067 0.016 4.1661025
rs11671664 GIPR 9,453 A/G 0.11 20.17 0.025 2.64610211 20.17 0.026 2.63610211
rs4502156 C2CD4A (NLF1/VPS13C) 10,787 T/C 0.52 20.092 0.014 1.14610210 0.0035 0.015 0.82
rs3757840 GCK 10,322 T/G 0.45 20.090 0.015 1.3461029 20.083 0.016 1.3061027
rs12549902 ANK1 14,834 A/G 0.58 20.060 0.010 1.0161028 20.036 0.011 0.00083
The results are from the meta-analyses of the discovery GWAS, CardioMetabochip and de novo genotyping. Results are reported for the directly genotyped and imputed
SNPs tested for association with insulin secretion measured as CIR and AUCIns/AUCGluc (trait abbreviations are listed in the Methods ‘‘Phenotype definition’’ section).
Freq denotes the allele frequency of the insulin secretion-reducing allele. N = sample size. Since the index SNP rs933360 (A/G) from the discovery GWAS was not present
on the CardioMetabochip platform, a variant (rs6943153 (C/T)) in strong LD with the former (r2 = 0.82) was used as a proxy SNP for the meta-analyses.
doi:10.1371/journal.pgen.1004235.t001
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Expression of GRB10 in Human Muscle and Adipose
Tissue
Given that we observed differences in insulin sensitivity when
the risk A-allele of SNP rs933360 was inherited from the mother
compared to the father, and that GRB10 is an inhibitor of insulin
signaling, we also explored whether the SNP would influence
expression of the GRB10 gene in human skeletal muscle and
adipose tissue [20,21]. We observed that carriers of the A-allele
had decreased GRB10 mRNA level in muscle (N = 38, b=20.405,
p= 0.013) and adipose tissue (N = 1,375, b=20.038, p= 0.005).
Effects of GRB10 on Islet Function
To gain insight into the mechanisms by which GRB10 influences
pancreatic b- and a-cell function, we disrupted Grb10 expression in
rat insulinoma INS-1 cells by siRNA and in human islets by
shRNA achieved by lentiviral transfection. There was a clear
reduction in GSIS after siRNA-disruption of Grb10 in the INS-1
cell line lacking glucagon (Figure 4A). In human pancreatic islets,
decreased GRB10 expression resulted in a reduction of both insulin
and glucagon secretion and expression (Figure 4B, C). In addition,
GRB10 knock-down was also associated with a decrease in
forskolin- and K+-stimulated glucagon secretion (Figure S8A).
Grb10 has been reported to both increase [22] and decrease
[23] apoptosis in islets, in addition to its effects on insulin signaling
[22]. Disruption of GRB10 was associated with a significant
reduction in the number of viable human pancreatic islets, as
assessed by an MTS technique, supporting recent data in mice
using shRNA to disrupt Grb10 in pancreatic islets [22] (Figure
S8C).
Discussion
The present study provides mechanistic insights into the role of
GRB10 in the regulation of islet function and glucose metabolism
in man. First, the A-allele of the GRB10 rs933360 variant was
associated with different effects on insulin secretion, sensitivity and
glucose concentrations, if transmitted from fathers or mothers.
Second, disruption of GRB10 in human islets resulted in a
reduction of both insulin and glucagon secretion, the latter of
which can provide an additional explanation for the reduction in
glucose levels despite reduced insulin levels. Third, metabolic
effects of GRB10 on glucose homeostasis involved tissue-specific
methylation and parental imprinting.
GRB10 is an adaptor protein, which interacts with a number of
receptor tyrosine kinases and signaling molecules and serves as a
down-regulator of insulin receptor activity [24]. GRB10 partici-
pates in phosphorylation and activation of the mTORC1 protein,
which is a central regulator of cellular metabolism, growth and
survival [25]. Studies in mice have shown an abundant expression
of Grb10 in brain, fat, muscle and heart, and with the highest
expression in pancreas [26].
An interesting observation in the present study was that the
common variant rs933360 in the GRB10 gene was associated with
reduced GSIS, enhanced insulin sensitivity and reduced glucose
levels when inherited from the mother. On the contrary, the
Figure 2. Parent-of-origin effect of GRB10 rs933360 on insulin secretion and glucose levels. (A) No significant effect for CIR was observed
from the paternally transmitted A-allele. (B) Carriers of the maternally transmitted A-allele showed lower CIR compared to the G-allele. (C) Carriers of
the paternally transmitted A-allele had elevated fasting plasma glucose levels, whereas (D) the maternally transmitted A-allele was associated with
lower fasting plasma glucose levels. Fin-Swe = Trios from Finland and Sweden, Amish = Amish Family Diabetes Study, Kuopio = Kuopio Offspring
Study.
doi:10.1371/journal.pgen.1004235.g002
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paternally transmitted allele was associated with elevated glucose level
and increased risk for T2D. These findings might partially explain the
modest or lack of effects seen in several studies for variants in the
GRB10 gene on T2D risk [27]. The effect on insulin sensitivity is
indirectly supported by the view that carriers of the A-allele showed
decreased expression of GRB10 in skeletal muscle and adipose tissue.
Figure 3. GRB10 expression in human islets. (A) Immunostainings demonstrating that GRB10 (green, panel A, E) is abundantly expressed in b-
(panel B, D), a- (panel C, D) and d-cells (panel F, G) in human pancreatic islets. Arrows indicate co-localization with insulin (panel D) and somatostatin
(panel G). Arrowheads indicate co-localization with glucagon (panel D). Scale bar = 50 mm. (B) Schematic representation of the GRB10 gene and SNPs
investigated in the present study. Grey boxes = untranslated exons. Black boxes = translated exons. (C) Examples of RT-PCR on islet cDNA (top six
rows) and PCR on genomic DNA (gDNA, bottom row) from two individuals heterozygous for the reporter SNP rs1800504. The first column states the
forward primer location of each PCR and a forward primer in exon 3 captures all transcripts. The peaks show the Sanger sequencing trace across
rs1800504, which is underlined (A: green trace, G: black trace). Percentages indicate the contribution from the paternal allele (P.A.) (G-allele in the first
case, A-allele in the second case). The paternal genotype is identified assuming complete maternal imprinting of the UN2 promoter, in line with
previous findings [12]. A sequence of heterozygous genomic DNA (gDNA) is shown on the bottom for comparison (50%-50%). (D) To study if DNA
methylation of GRB10 is tissue-specific, the degree of methylation was analyzed at 3 CpG sites located ,31.7 kb downstream of rs933360 in both
human pancreatic islets of 98 donors and PBL from 6 trios using EpiTYPER. The exact position of each analyzed CpG site in relation to rs933360 is
given in the figure. Data are presented as mean 6 SEM. * p,0.05 for difference in methylation between human islets and PBL. (E) The GRB10 mRNA
levels correlated negatively with the degree of methylation at the CpG site located 31,675 bp downstream of GRB10 rs933360.
doi:10.1371/journal.pgen.1004235.g003
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Another potential explanation could be the effect of GRB10 on
glucagon secretion. Unfortunately, due to lack of samples for glucagon
measurements, we were not able to test this directly in the trios.
To further explore whether GRB10 influences glucagon
secretion/expression and thereby mechanisms by which GRB10
might influence glucose metabolism, we disrupted GBR10 in
human pancreatic islets. While Grb10 knock-down in the rat
insulinoma cell line INS-1 lacking glucagon resulted in marked
reduction of insulin, GRB10 knock-down in human pancreatic
islets resulted in reduction in both insulin and glucagon secretion
and expression. The effect on glucagon seen in human islets is in
line with data from mice, showing reduced glucagon levels after
Grb10 disruption using shRNA [22].
Since rs933360 is located in intron 2 of the GRB10 gene, one
could envision an effect on gene expression. This could be a
possible mechanism, as monoallelic and isoform-specific expres-
sion of GRB10 has been reported in fetal brain, skeletal muscle and
in the placental trophoblasts [11,12]. Unfortunately, we could not
observe any effect of the SNP on expression of the GRB10
transcript in islets, nor could we examine parent-of-origin effects in
the islets from human cadaver donors, as we lacked information
on the parents. However, using two different strategies we could
demonstrate allelic imbalance for SNPs in the GRB10 gene,
leaving this possibility open. In line with earlier findings, we also
identified three transcripts arising from alternative GBR10
promoters, with the paternally expressed UN2 isoform being
imprinted from one parent in islets. However, there is sufficient
amount of the maternally expressed UN1a isoform in islets to
allow an effect of the maternally transmitted allele, which could
contribute to the stronger effect of the maternal allele as described
above.
Genetic imprinting is usually a consequence of increased DNA
methylation. In line with previous reports [11,12], we observed
tissue-specific methylation of GRB10, showing highest degree of
methylation in human pancreatic islets, which was associated with
decreased expression of GRB10. Although this relationship was not
influenced by the SNP in human pancreatic islets, there was a
tendency for an effect of the SNP on degree of methylation in
PBL.
Our study has some limitations. Despite large sample size for
measurements of insulin secretion, we did neither have samples
with measurements of glucagon in the trios, nor did we have
parental information for islet donors. Also, tissue limitations
prevented us from directly exploring methylation patterns and
imprinting in trios. Finally, although this is the largest meta-
analysis for insulin secretion to date, we discovered only one novel
locus influencing GSIS. While this could be a consequence of
limited power, another plausible explanation is that many
homeostatic mechanisms, as well as parent-of-origin specific
effects, would dilute and neutralize such effects.
In conclusion, our data demonstrate a complex genetic
regulation of GRB10 function in human islets with different effects
of paternally and maternally transmitted alleles. Together, these
findings suggest that tissue-specific methylation and possibly
imprinting of GRB10 can influence glucose metabolism and
contribute to T2D pathogenesis. The data also emphasize the
need in genetic studies to consider whether disease risk alleles are
inherited from the mother or the father.
Methods
Ethics Statement
All studies were approved by local research ethics committees,
and all participants gave informed consent. All procedures in
human islets were approved by the ethics committees at the
Uppsala and Lund Universities and informed consent obtained by
appropriate measures from donors or their relatives.
Figure 4. Effects of disrupted GRB10 through knock-down on
islet function. (A) Disrupted GRB10 in INS-1 rat b-cells markedly
reduced glucose-stimulated insulin secretion. (B) GRB10 knock-down
showed reduced glucose-stimulated insulin secretion at 20 mM glucose
and glucagon secretion at 1 mM glucose in human pancreatic islets
(Ninsulin = 7, Nglucagon = 6 donors of human pancreatic islets; 3–6
measurements in each experiment for each donor). (C) GRB10 knock-
down resulted in a reduction of insulin and glucagon mRNA expression
(N = 3 donors of human pancreatic islets; 3 measurements in each
experiment for each donor). * p,0.05; ** p,0.01, *** p,0.001. Error
bars denote SEM.
doi:10.1371/journal.pgen.1004235.g004
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Meta-Analyses of Genome-Wide Association and
CardioMetabochip Studies
Association analyses of insulin secretion and action traits were
performed within 11 cohorts participating in the Meta-Analysis of
Glucose- and Insulin-related traits Consortium (MAGIC) in a total
of up to 10,831 individuals. In the discovery stage 1, we performed
a meta-analysis of 6 GWASs (Diabetes Genetics Initiative (DGI),
Amish Family Diabetes Study, Sorbs, Helsinki Birth Cohort Study
(HBCS), French Obese Adults, and Relationship between Insulin
Sensitivity and Cardiovascular disease Study (RISC)) for glucose-
stimulated insulin secretion (GSIS) during an oral glucose-
tolerance test (OGTT) at 3 time points (fasting, 30 min,
120 min) for primary traits measured as (1) insulin response to
glucose after the first 30 min estimated as corrected insulin
response (CIR), and (2) overall insulin response to glucose
estimated as area under the curve (AUC) for insulin over a total
AUC for glucose (AUCIns/AUCGluc) in up to 5,318 non-diabetic
individuals (Table S1A).
As none of the traits gave genome-wide significant association,
we selected the top 50 independent signals from both primary and
secondary traits (see ‘‘Phenotype Definition’’ below) after LD
pruning (r2,0.2). Signals prioritized for replication were ranked
by the number of associations observed at primary traits and/or
secondary traits, association p-value and number of times the
signal was observed across the traits (more than 2). We selected 14
SNPs for replication genotyping and follow-up analyses, out of
which 3 loci were based on biological relevance: GRB10 [13]
(rs933360, discovery p-value (CIR) = 5.0961026), UCN3 (rs11253130,
discovery p-value (Ins30adjBMI) = 9.4661027) and INADL (rs2476186,
discovery p-value (AUCIns/AUCGluc) = 1.88610
26). Replication
stage 2A de novo genotyping was undertaken in five population-
based studies (Botnia-PPP, ULSAM, METSIM, BPS and Hague-
nau; only GWAS index SNP rs933360 in the latter three; max
N = 15,273) (Table S1A, S2A). Replication stage 2B in silico was
undertaken using an iSelect CardioMetabochip array (CM)
(Illumina, San Diego, CA, USA) to genotype data in 5 independent
population-based studies (Botnia-PPP, ULSAM, Ely, DR’s Extra
and METSIM) including up to 5,513 individuals (Table S1A).
The GWAS/CM (stage 1 and stage 2B) data including 93,896
SNPs were pooled together with the de novo genotyping results from
stage 2A for non-overlapping individuals. In this meta-analysis, we
defined all independent (r2,0.2) genome-wide significant (p-
value,561028) association signals for insulin secretion traits at
8 genomic loci (Table 1).
Phenotype Definitions
The primary insulin secretion and action indices were: (i)
Corrected Insulin Response (CIR) = (1006 insulin at 30 min)/
(glucose at 30 min6(glucose at 30 min–3.89)), and (ii) ratio of the
area under the curve (AUC) for AUC insulin/AUC glucose
(AUCIns/AUCGluc, mU/mmol) calculated using the trapezium
rule [28]. Insulin sensitivity index (ISI) = 10,000/! (fasting plasma
glucose (mg/dl)6fasting insulin6mean glucose during OGTT
(mg/dl)6mean insulin during OGTT). Secondary insulin secre-
tion and action indices during OGTT were: (i) disposition index
(DI) = CIR6ISI; (ii) insulin at 30 min (Ins30); (iii) incremental
insulin at 30 min (Increm30) = insulin 30 min – fasting insulin; (iv)
insulin response to glucose during the first 30 min adjusted for
BMI (Ins30adjBMI) = insulin at 30 min/(glucose at 30 min6
BMI); (v) area under the curve (AUC) of insulin levels during
OGTT (AUCIns, mU*min/l). Individuals with missing data on any
of the three time points included in the AUC calculation were
excluded.
Statistical Analysis
Linear regression models were used for association of pheno-
types (z-score residuals of insulin secretion and action traits) with
genotypes coded additively. Discovery (stage 1) GWAS analyses
were carried out using a statistical tool that was able to account for
genotype uncertainty, SNPTEST [29], or by using allele dosages
in the linear regression model in MACH2QTL [30,31],
probABEL [32], corrected for residual inflation of the test statistics
using the genomic control method [33]. The meta-analyses of
effect sizes were performed with the fixed-effect inverse-variance
method using GWAMA [34]. The GC correction was applied only
once to cohort-specific results before including them into the meta-
analyses. Sex-differentiated analyses were performed using
GWAMA, with an assumed heterogeneity p-value of ,0.05.
Effect sizes for glucose levels were estimated using a fixed-effect
model using the metaphor package for R version 2.14.2 (http://
www.r-project.org/).
Parent-of-Origin Effect Analysis on Insulin Secretion and
Glucose Levels
The Trios from Finland and Sweden, Amish Family Diabetes
Study and Kuopio Offspring Study (Table S1A, S3A, B) consisted
of a father, a mother and an offspring. Genotype phase was
determined using Merlin and then analyzed using Solar, which
uses the kinship matrix to account for family. Meta-analysis on
insulin secretion and action and glucose levels during OGTT (as
earlier described) was performed using a fixed-effect model.
Analyses were performed on IBM SPSS Statistics 20.0 (IBM
Corp., Chicago, IL, USA), R version 2.14.2 with the metaphor
package (http://www.r-project.org/) and MMAP (MMAP: mixed
models analysis for pedigrees and populations, http://edn.som.
umaryland.edu/mmap/index.php).
The Transmission Disequilibrium Test (TDT) used to compare
frequencies of transmission of the two alleles from heterozygote
parents to an affected offspring was performed using PLINK
(http://pngu.mgh.harvard.edu/purcell/plink/) [35] (Table S3A).
The deviations from Mendelian transmissions were assessed and the
power of the test was enhanced by incorporating information from
phenotypically discordant parents (ParenTDT) [14]. To confirm
the association, another independent test was performed, which can
accommodate any type of genetic model and family construction,
i.e. the Family Based Association Test (FBAT) [15]. Quantitative
traits related to glucose metabolism and insulin secretion were
assessed in non-diabetic individuals using qTDT and parent-of-
origin effect tests. IBD estimates were calculated using Merlin.
Permutations were performed using QFAM (PLINK). OGTT
values were natural log-transformed and adjusted for BMI.
Association of GRB10 rs933360 with Glucagon Levels
The Botnia Prevalence, Prediction and Prevention of diabetes
(Botnia-PPP) study is a population-based study from the Botnia
region of Western Finland and has previously been described [36].
For this study, we selected 4,641 non-diabetic individuals above
the age of 18. Linear regression analysis assuming an additive
genetic risk model was performed to evaluate genotype-phenotype
association. Hyperglycemic individuals were identified based on
previous diagnosis, fasting plasma glucose levels of 5.5–6.9 mmol/l
and 2 hr plasma glucose levels of 7.8–11.1 mmol/l (Table S5).
Association of GRB10 rs933360 with GRB10 mRNA in
Human Muscle
A subgroup of 203 men with IGT at screening visit selected
from the MPP study participated 20 years later in more extensive
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metabolic studies, including a new OGTT, a euglycemic-hyperin-
sulinemic clamp combined with indirect calorimetry and infusion of
[3-3H]glucose [37,38]. The men were similar in age, but had
varying degrees of glucose tolerance; 69 were in the normal range,
52 had IFG and/or IGT, and 82 had T2D. T2D patients were
either treated with diet alone (42%) or with oral hypoglycemic
agents, which were withheld the day before the test. Microarray
expression data were analyzed as previously described [20].
Association of GRB10 rs933360 with Future Risk for T2D
The Malmo¨ Preventive Project (MPP) is a large population-
based prospective study from the city of Malmo¨, Sweden, and has
previously been described [17]. For this study, we selected 16,715
non-diabetic subjects, of whom 2,637 developed T2D during a
24.1 year mean follow-up period. The odds ratio for risk of
developing T2D was calculated using logistic regression analysis
assuming an additive genetic risk model. The analysis was adjusted
for age, sex, BMI, participation period and an interaction term
(participation period x sex) [10]. IBM SPSS Statistics 20.0 (IBM
Corp.) was used for the statistical analysis.
Human Pancreatic Islets
Islets from cadaver donors were provided by the Nordic Islet
Transplantation Program (www.nordicislets.org) by the courtesy of
Prof. Olle Korsgren, Uppsala University, Sweden. The microarray
experiments (Human Gene 1.0 ST whole transcript) were
performed on islets isolated from 81 normoglycemic (mean6SEM;
age 56.361.3 yrs, BMI 25.760.4 kg/m2, HbA1c 5.560.04%)
and 46 hyperglycemic (age 60.361.2 yrs, BMI 27.860.6 kg/m2,
HbA1c 6.660.1%) islet donors. RNA products were fragmented
and hybridized to the GeneChip Human HG U 133A Array
(Affymetrix, Santa Clara, CA, USA) [39]. Statistical analyses of
expression data were performed using two-tailed Spearman’s T-
test.
Immunocytochemistry
Immunocytochemistry with antibodies for GRB10 (K20)18
(code sc-1026, Santa Cruz Biotech. Inc., CA, USA), insulin,
glucagon and somatostatin was performed on human pancreatic
sections as previously described [40].
RNA Sequencing of Human Islets
RNA from 48 human pancreatic islets donors (24 with HbA1c
,5.5% and 24 donors with HbA1c .6.0%) was isolated and
purified using miRNeasy kit (Qiagen, Hilden, Germany). As
quality thresholds for RNA samples, we demanded RIN values
.8, 28S/18S ratio .1.5 and the absorbance ratios 260/280 .1.8
and 260/230 .1. Sample preparation for sequencing reactions
was performed using TrueSeq sample prep kit (Illumina).
Fragmentation was performed using inbuilt fragmentation in the
sample prep kit to obtain fragments of approximately 300 bp in
length. Sequencing was performed on the Illumina HiSeq 2000
platform. Obtained sequenced reads were transformed into .qseq
files using the Illumina pipeline. Alignment of the reads was
performed using the TopHat short read aligner (tophat.cbcb.um-
d.edu). Cufflinks (cufflinks.cbcb.umd.edu) was used for splice
variant calling.
Identification of GRB10 Splice Variants and Measurement
of Allelic Imbalance
Analytical RT-PCRs were performed on cDNA from human
islet, visceral fat, subcutaneous fat, liver and muscle in 15 ml
reactions using 7.5 ml AmpliTaq Gold PCR Master Mix (Applied
Biosystems, Foster City, CA, USA) supplemented with 0.75 ml
DMSO and 1.5 mmol/l of forward and reverse primers. The
following primers were used in various combinations: UN1fw:
CAAACGCCTGCCTGACGACTG, UN1Afw: GCCCGGGA-
CAGTCTTGAGC, UN2fw: GGCGCACACGCAGCGAC, UN3fw:
ACCACCTACATCAGAGCTGACTGCC, 1bfw: CCTGGGCT-
ACCCTCTGCTTC, 3fw: GCCTGTACTCGGCCTGCAGC, 9fw:
GCCCCTACAGACCACGGGCT, 11fw: GCTGTCCCCGTTC-
TCGACGC, 3rv: ATGTGCACAGGCTGGGAGCG, 7rv: CTGG-
CTGTCATGTCTGCT, 11rv: CTGCTGAGGGATTCGGT, 16rv:
GGATGCAGTGGTGCTTGA, the names referring to the target
exon. PCR reactions were carried out with 53uC annealing
temperature and over 50 cycles. Products were analyzed on 2%
agarose. Prior to sequencing, 2.5 ml PCR product was treated with
0.5 ml ExoSAP-IT (USB, Cleveland, OH, USA) at 37uC for 30 min
followed by deactivation at 80uC for 15 min. Subsequently, 1 ml was
sequenced in both directions using BigDye 3.1 according to the
manufacturer’s protocol (Applied Biosystems). The sequence reactions
were purified and analyzed by GATC Biotech AG (Konstanz,
Germany).
Allelic imbalance measurements were performed by RT-PCR
using the reverse primer 3rv and either of the forward primers
UN1afw, UN1fw, UN2fw, UN3fw, 1bfw or 3fw in samples
heterozygous for the common SNP rs1800504 (GRB10 exon3).
The individual contribution from each allele was measured at the
position of rs1800504 using Sanger sequence traces and the
software Mutation Surveyor (Soft Genetics, PA, USA). Allelic
imbalance in GRB10 was also detected by a different method:
After extensive quality and coverage filtering, we did a Fisher exact
test for comparing the ratio of reference/alternative alleles in the
exome sequencing vs. RNA-seq for each sample. Exome
sequencing was performed using the Illumina exome sequencing
protocols (TruSeq DNA sample preparation Kit v2).
Methylation Studies
Sequenom’s MassARRAY EpiTYPER protocol was applied to
measure DNA methylation (Sequenom, San Diego, CA, USA) in
human islets of 96 donors and peripheral blood lymphocytes (PBL) of
6 diabetic offspring trios (18 individuals). EpiDesigner was used for
assay design at GRB10 and the primer sequences were the following;
forward: aggaagagagGGGAAAGGGTGTTAAATTGTTTATG,
reverse: cagtaatacgactcactatagggagaaggctTTTTAAACCCCTCA-
AATTCAAAAAT. 500 ng genomic DNA was bisulfite-treated with
the EZ DNA Methylation kit (Zymo Research, Orange, CA, USA).
The spectra were analyzed and the methylation ratios were obtained
by the EpiTYPER software v.1.0.1. Global methylation analyses
were performed on DNA extracted from PBL on the Illumina
Infinium 450 Bead Chip and the chips were scanned on an Illumina
iScan as per protocol (Illumina). 1 mg of DNA was bisulfite-treated
according to protocol (EZ DNA Methylation Kit, Zymo research).
For analysis, the Genome Studio Methylation Module of the
Genome studio Genome Browser was used, which facilitates
integration of the SNP and CpG location data (NCBI build 37).
Methylation status was assessed after normalization to internal
controls and background subtraction and expressed as b. The b
values for the CpG sites were mapped to the gene and plotted to give
an overview of methylation status for the region of interest (Figure
S7D).
Disruption of GRB10 for Insulin and Glucagon Secretion
Analyses
shRNA-mediated knock-down of GRB10 in human
pancreatic islets. Specific silencing of endogenous hGRB10
was achieved using a lentiviral-based shRNA-silencing technique
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(Santa Cruz Biotech. Inc.). Isolated human islets were incubated at
2.8 mmol/l glucose + Polybree for 90 min. Thereafter, the
medium was removed and the islets were washed before culture
medium + lentiviral particles containing GRB10 shRNA (5 ml/ml)
was added, and the islets were cultured for 36 h at 5 mmol/l
glucose. For comparison, a scramble (lentiviral particles without
targeting any specific region) served as control. Insulin and
glucagon were measured using a radioimmunoassay kit (Electro-
box, Stockhom, Euro-Diagnostica, Malmo¨, Sweden).
siRNA-mediated knock-down of Grb10 in INS-1 832/13
cells. For Grb10 small interfering RNA (siRNA) experiments,
20–25-nucleotide stealth-prevalidated siRNA duplex designed for
rat Grb10 (Santa Cruz Biotech. Inc.) was used. INS-1 832/13 cells
were seeded in 24-well plates at a density of ,56105 cells in
culture media without antibiotics and transfected with Dharma-
FECT 1 (Dharmacon, Lafayette, CO, USA) according to the
manufacturer’s instructions.
Assessment of b-cell Viability
Human pancreatic b-cell viability assay was performed using a
CellTiter 96 AQueous One Solution Cell Proliferation Assay
Reagent (Promega, Stockholm, Sweden) according to the manu-
facturer’s instructions. The actual performance is based on the
spectrophotometric detection of a colored formazan product
converted from a 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethox-
yphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) compound by
NADPH or NADH via metabolically active cells.
Supporting Information
Figure S1 Regional plots for the top 8 hits reaching genome-
wide significance level. Association with insulin secretion measured
as corrected insulin response (CIR) at 30 min of OGTT for the
novel genetic variant GRB10 rs933360 (A) and the previously
reported T2D and glycemic trait variants HHEX/IDE/KIF11 (B),
MTNR1B (C), CDKAL1 (D), C2CD4A (NLF1) (E), ANK1 (F), GCK
(G) and GIPR (H).
(TIFF)
Figure S2 Genome-wide quantile-quantile (Q-Q) and Manhat-
tan plots for insulin secretion and action traits analyzed in the
present study. Corrected insulin response (CIR) to glucose at
30 min of OGTT (A, B), insulin sensitivity index (C, D), insulin
response adjusted for insulin sensitivity (CIR adj ISI) (E, F),
disposition index (G, H), insulin level at 30 min of OGTT (I, J),
incremental insulin at 30 min of OGTT (K, L), insulin level at
30 min of OGTT adjusted for BMI (M, N), area under the insulin
curve (AUC ins) (O, P) and ratio between area under the insulin
and glucose curves (AUC ins/AUC gluc) (Q, R).
(TIFF)
Figure S3 Meta-analysis for association of GRB10 rs933360 with
fasting plasma glucose in the participating cohorts. The insulin-
reducing allele was associated with lower fasting plasma glucose
levels in all individuals.
(TIFF)
Figure S4 GRB10 mRNA levels in human islets. (A) GRB10
expression levels did not significantly differ between normoglyce-
mic (HbA1c ,5.4%) and hyperglycemic (HbA1c .6%) islet
donors (T-test, p = 0.32). (B) There was no significant difference in
GRB10 mRNA expression levels between carriers of different
GRB10 genotypes (linear regression, pnormoglycemic = 0.11; phypergly-
cemic = 0.25). (C) Correlation between GRB10 and GCG (glucagon),
and GRB10 and INS (insulin) mRNA expression in islets from
normoglycemic (HbA1c ,6%, N = 51) and hyperglycemic donors
(HbA1c .6%, N = 27). Error bars denote SE.
(TIFF)
Figure S5 Schematic representation of the GRB10 gene and its
transcripts. The 59 exon arrangements of GRB10 splice variants
were identified in human fat and islet samples by RT-PCR and
Sanger sequencing. The exon order at the gene level is shown in
the top row. UCSC IDs of matching transcripts are indicated to
the right.
(TIFF)
Figure S6 Allele-specific expression analysis of the GRB10 59-
end in islet, muscle, liver and fat tissue. Transcripts containing
exon UN2 are exclusively expressed from one allele (presumably
paternal), whereas transcripts containing the upstream exons UN1
or UN1a derive from both alleles to a varying degree. UN1a, UN1
and UN2 are mutually exclusive exons. A sequence of heterozy-
gous genomic DNA (gDNA) is shown on top for comparison (50%-
50%). rs1800504 in exon 3 was used as a reporter SNP for the
intronic index SNP rs933360.
(TIFF)
Figure S7 Pictorial representation of GRB10 methylation status
in human islets and peripheral blood lymphocytes. The impact of
rs933360 on DNA methylation of three CpG sites analyzed using
EpiTYPER in human islets (N = 96) (A) and peripheral blood
lymphocytes (PBL, N = 18) (B). (C) The GRB10 mRNA levels
correlated negatively with the degree of methylation at CpG sites
located 8,196 bp downstream of rs933360 of the GRB10 gene in
human pancreatic islets (N = 66). (D) Methylation status was tested
for 44 CpG sites using the Illumina Infinium 450 K global
methylation assay and is represented in the graph above the gene
structure. The numbers on the Y-axis on the right indicate the
mean b values showing methylation status. The colored boxes
represent the exons of the four isoforms annotated in the NCBI.
Arrows indicate position of the SNPs tested for association. Distances
between nearest CpG site tested and: (i) rs6943153 = 6.9 kb, (ii)
rs933360 = 8.2 kb and (iii) rs2237457 = 13.8 kb. Hapmap does not
show the linkage of the tested SNPs with any of the SNPs tested for
methylation status. The CpG sites in the proximity were methylated
(b.0.8). GRB10 is presented on a reverse strand.
(TIFF)
Figure S8 Effect of GRB10 disruption on islet function and cell
survival in human pancreatic islets. (A) GRB10 knock-down
showed reduced glucagon secretion at 1 mM glucose, particularly
stronger for forskolin- and K+-stimulated glucagon secretion.
Reduced GRB10 expression in human pancreatic islets had modest
effects on insulin secretion, i.e. a slight increase in insulin levels at
1 mM glucose. Ninsulin = 4 and Nglucagon = 3 donors of human
pancreatic islets; up to 6 measurements in each experiment for
each donor. (B) Effect of GRB10 disruption on insulin and
glucagon content (1 non-diabetic donor, 6 measurements in each
experiment). (C) GRB10 knock-down resulted in a reduction of the
number of viable cells in human pancreatic islets. (D) Effect of
GRB10 disruption on caspase-3 mRNA expression (2 non-diabetic
donors, 3 measurements in each experiment). * p,0.05, ***
p,0.001.
(TIFF)
Table S1 (A) Characteristics of cohorts and study details of
analysis metrics and methods. (B) Heritability estimates of
parameters of insulin secretion and action indices used in the study.
(C) Spearman correlations between insulin secretion and action
indices for the non-diabetic participants of the Botnia-PPP study.
(XLS)
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Table S2 (A) Association results of selected SNPs from the
discovery GWAS, the CardioMetabochip and the de novo
replication genotyping. (B) Meta-analysis of GWAS and Cardio-
Metabochip studies: association results with parameters of insulin
secretion and insulin action during OGTT for loci previously
associated with type 2 diabetes (T2D), 2 hour plasma glucose
during OGTT (2hPG), fasting plasma glucose (FGlu), fasting
insulin (FIns) and obesity.
(XLS)
Table S3 (A) Assessing transmissions of GRB10 rs933360 and
rs6943153 alleles in the Trios from Finland and Sweden. (B)
Parent-of-origin effect of GRB10 rs933360 on parameters of
insulin secretion and insulin action, and glucose levels during
OGTT in the non-diabetic offspring from the Trio cohorts.
(XLS)
Table S4 Odds ratios for GRB10 rs933360 for risk of T2D in the
MPP study.
(XLS)
Table S5 (A) Descriptive statistics for the Botnia-PPP cohort. (B)
Association between GRB10 rs933360 and glucagon levels in the
Botnia-PPP cohort.
(XLS)
Table S6 GRB10 SNPs associated with fasting and 2 hr glucose
levels in 361 non-diabetic individuals from the DGI GWAS study.
(XLS)
Table S7 Measurements of allelic imbalance in the 8 heterozy-
gous carriers of GRB10 rs1800504 in human islets.
(XLS)
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